Pro-fibrotic M2 macrophage markers may increase the risk for COVID19 in type 2 diabetes with obesity
- 16 September 2020
- journal article
- letter
- Published by Elsevier in Metabolism
- Vol. 112, 154374
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- commentary: COVID-19 and Obesity: Exploring Biologic Vulnerabilities, Structural Disparities, and Weight StigmaMetabolism, 2020
- Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe COVID-19 patientsEBioMedicine, 2020
- Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophagesNature Reviews Immunology, 2020
- Effect of induced hypoglycemia on inflammation and oxidative stress in type 2 diabetes and control subjectsScientific Reports, 2020
- Determinants of Serum Concentrations of Lipopolysaccharide-Binding Protein (LBP) in the Adult Population: The Role of ObesityPLOS ONE, 2013
- A Marker of Endotoxemia Is Associated With Obesity and Related Metabolic Disorders in Apparently Healthy ChineseDiabetes Care, 2010
- Lipopolysaccharide-binding protein and CD14 are increased in the bronchoalveolar lavage fluid of smokersEuropean Respiratory Journal, 2008
- A Vicious Circle of Alveolar Macrophages and Fibroblasts Perpetuates Pulmonary Fibrosis via CCL18American Journal of Respiratory and Critical Care Medicine, 2006
- The chemokine system in diverse forms of macrophage activation and polarizationTrends in Immunology, 2004
- CONCENTRATIONS OF LIPOPOLYSACCHARIDE-BINDING PROTEIN, BACTERICIDAL/PERMEABILITY-INCREASING PROTEIN, SOLUBLE CD14 AND PLASMA LIPIDS IN RELATION TO ENDOTOXAEMIA IN PATIENTS WITH ALCOHOLIC LIVER DISEASEAlcohol and Alcoholism, 2002